$GRI News

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease

Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio Receives Notice Of Allowance From UAE Patent Office For UAE Patent Titled Prevention And Treatment Of Inflammatory Conditions

Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI stock has given up its prior gain. GRI Bio shares were trading higher. The company reported FY25 financial results.

GRI stock has given up its prior gain. GRI Bio shares were trading higher. The company reported FY25 financial results.